Ulcerative colitis (UC) is a chronic intermittent relapsing disorder of the large intestine and rectum. Treatment typically begins with conventional agents (e.g., 5-aminosalicylic acids [5-ASAs]) that are often effective for those patients with mild to moderate disease. Treatment then progresses to more-potent drugs, such as immunosuppressants and/or biologics, as needed. Among the biologics, tumor necrosis factor (TNF)-alpha inhibitors (Janssen’s Remicade and AbbVie’s Humira) and a cell adhesion molecule (CAM) inhibitor (Takeda’s Entyvio) are the mainstays of treatment, followed by an IL-12/23 inhibitor (Janssen’s Stelara). However, later-to-market oral targeted therapies, such as Janus-activated kinase (JAK) inhibitors (Pfizer’s Xeljanz / Xeljanz XR and AbbVie’s Rinvoq) and a sphingosine 1-phosphate receptor (S1P-R) modulator (BMS’s Zeposia), are increasing the market competition among later-line targeted therapies. The impending entry of adalimumab biosimilars in the United States will further impact market dynamics.
For the abstract please provide an overview paragraph here and then fill in the bulleted sections below. Feel free to modify the bulleted section. Leverage content from a brochure if you have one.
Markets covered: United States.
Key companies: AbbVie, Janssen, Pfizer, Takeda, UCB, BMS.
Key drugs: Humira, Remicade, biosimilar infliximab, Entyvio, Stelara, Xeljanz / Xeljanz XR, Simponi, Zeposia, Rinvoq, aminosalicylates, immunosuppressants.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.